journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://www.readbyqxmd.com/read/29710343/when-you-hear-hoofbeats-look-for-horses-not-zebras
#1
Yuki Kataoka, Azusa Sakurai, Emiko Saito
No abstract text is available yet for this article.
April 26, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710327/some-thoughts-on-exposure-to-the-world-trade-center-wreckage-and-cancer
#2
Otis W Brawley
No abstract text is available yet for this article.
April 26, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710216/association-of-dasatinib-with-progression-free-survival-among-patients-with-advanced-gastrointestinal-stromal-tumors-resistant-to-imatinib
#3
Scott M Schuetze, Vanessa Bolejack, Dafydd G Thomas, Margaret von Mehren, Shreyaskumar Patel, Brian Samuels, Edwin Choy, Gina D'Amato, Arthur P Staddon, Kristen N Ganjoo, Warren A Chow, Daniel A Rushing, Charles A Forscher, Dennis A Priebat, David M Loeb, Rashmi Chugh, Scott Okuno, Denise K Reinke, Laurence H Baker
Importance: Gastrointestinal stromal tumors (GISTs) are life-threatening when metastatic or not amenable to surgical removal. In a few patients with advanced GISTs refractory to imatinib mesylate, treatment with sunitinib malate followed by regorafenib provides tumor control; however, additional active treatments are needed for most patients. Objective: To evaluate the 6-month progression-free survival (PFS), tumor objective response, and overall survival rates in patients with GISTs treated with dasatinib...
April 26, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710195/multiple-myeloma-and-its-precursor-disease-among-firefighters-exposed-to-the-world-trade-center-disaster
#4
Ola Landgren, Rachel Zeig-Owens, Orsolya Giricz, David Goldfarb, Kaznouri Murata, Katie Thoren, Lakshmi Ramanathan, Malin Hultcrantz, Ahmet Dogan, George Nwankwo, Ulrich Steidl, Kith Pradhan, Charles B Hall, Hillel W Cohen, Nadia Jaber, Theresa Schwartz, Laura Crowley, Michael Crane, Shani Irby, Mayris P Webber, Amit Verma, David J Prezant
Importance: The World Trade Center (WTC) attacks on September 11, 2001, created an unprecedented environmental exposure to known and suspected carcinogens suggested to increase the risk of multiple myeloma. Multiple myeloma is consistently preceded by the precursor states of monoclonal gammopathy of undetermined significance (MGUS) and light-chain MGUS, detectable in peripheral blood. Objective: To characterize WTC-exposed firefighters with a diagnosis of multiple myeloma and to conduct a screening study for MGUS and light-chain MGUS...
April 26, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710129/total-costs-of-chimeric-antigen-receptor-t-cell-immunotherapy
#5
Inmaculada Hernandez, Vinay Prasad, Walid F Gellad
No abstract text is available yet for this article.
April 26, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710126/estimation-of-future-cancer-burden-among-rescue-and-recovery-workers-exposed-to-the-world-trade-center-disaster
#6
Ankura Singh, Rachel Zeig-Owens, William Moir, Charles B Hall, Theresa Schwartz, Madeline Vossbrinck, Nadia Jaber, Mayris P Webber, Kerry J Kelly, Viola Ortiz, Ellen Koffler, David J Prezant
Importance: Elevated rates of cancer have been reported in individuals exposed to the World Trade Center (WTC) disaster, including Fire Department of the City of New York (FDNY) rescue and recovery workers. Objective: To project the future burden of cancer in WTC-exposed FDNY rescue and recovery workers by estimating the 20-year cancer incidence. Design, Setting, and Participants: A total of 14 474 WTC-exposed FDNY employees who were cancer-free on January 1, 2012; subgroup analyses were conducted of the cohort's white male population (n = 12 374)...
April 26, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710106/when-you-hear-hoofbeats-look-for-horses-not-zebras-reply
#7
Yin P Hung, Lucian R Chirieac
No abstract text is available yet for this article.
April 26, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710084/national-distribution-of-cancer-genetic-testing-in-the-united-states-evidence-for-a-gender-disparity-in-hereditary-breast-and-ovarian-cancer
#8
Kimberly K Childers, Melinda Maggard-Gibbons, James Macinko, Christopher P Childers
No abstract text is available yet for this article.
April 26, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710067/the-power-of-trust
#9
Eric Mou, Lidia Schapira, Pamela Kunz
No abstract text is available yet for this article.
April 26, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710287/misclassification-of-upper-tract-urothelial-carcinoma-in-patients-with-lynch-syndrome-reply
#10
N Jewel Samadder, Jathine Wong, Karen Curtin
No abstract text is available yet for this article.
April 19, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710274/association-between-adjuvant-chemotherapy-and-overall-survival-in-patients-with-rectal-cancer-and-pathological-complete-response-after-neoadjuvant-chemotherapy-and-resection
#11
Fahima Dossa, Sergio A Acuna, Aaron S Rickles, Mariana Berho, Steven D Wexner, Fayez A Quereshy, Nancy N Baxter, Sami A Chadi
Importance: Although American guidelines recommend use of adjuvant chemotherapy in patients with locally advanced rectal cancer, individuals who achieve a pathological complete response (pCR) following neoadjuvant chemoradiotherapy are less likely to receive adjuvant treatment than incomplete responders. The association and resection of adjuvant chemotherapy with survival in patients with pCR is unclear. Objective: To determine whether patients with locally advanced rectal cancer who achieve pCR after neoadjuvant chemoradiation therapy and resection benefit from the administration of adjuvant chemotherapy...
April 19, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710272/association-of-adjuvant-chemotherapy-with-overall-survival-in-patients-with-rectal-cancer-and-pathologic-complete-response-following-neoadjuvant-chemotherapy-and-resection
#12
Patricio M Polanco, Ali A Mokdad, Hong Zhu, Michael A Choti, Sergio Huerta
Importance: Adjuvant chemotherapy (AC) in patients with rectal cancer with pathologic complete response following neoadjuvant chemoradiotherapy (nCRT) and resection is recommended by treatment guidelines. However, its role in this setting is equivocal because data supporting benefits are lacking. Objective: To compare the overall survival (OS) between AC and postoperative observation (OB) in patients with rectal cancer with pathologic complete response following nCRT and resection...
April 19, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710233/misclassification-of-upper-tract-urothelial-carcinoma-in-patients-with-lynch-syndrome
#13
Surena F Matin, Jonathan A Coleman
No abstract text is available yet for this article.
April 19, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710224/hormone-replacement-therapy-after-oophorectomy-and-breast-cancer-risk-among-brca1-mutation-carriers
#14
Joanne Kotsopoulos, Jacek Gronwald, Beth Y Karlan, Tomasz Huzarski, Nadine Tung, Pal Moller, Susan Armel, Henry T Lynch, Leigha Senter, Andrea Eisen, Christian F Singer, William D Foulkes, Michelle R Jacobson, Ping Sun, Jan Lubinski, Steven A Narod
Importance: Prophylactic bilateral salpingo-oophorectomy is recommended for BRCA1 mutation carriers to prevent ovarian cancer. Whether or not hormone replacement therapy (HRT) initiated after oophorectomy is associated with an increased risk of breast cancer has not been evaluated in a prospective study. Objective: To determine the association between HRT use and BRCA1-associated breast cancer. Design, Setting, and Participants: A prospective, longitudinal cohort study of BRCA1 and BRCA2 mutation carriers from 80 participating centers in 17 countries was conducted between 1995 and 2017 with a mean follow-up of 7...
April 19, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710211/addressing-financial-barriers-to-enrollment-in-clinical-trials
#15
Emily A Largent, Holly Fernandez Lynch
No abstract text is available yet for this article.
April 19, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710201/evaluating-treatment-effect-based-on-duration-of-response-for-a-comparative-oncology-study
#16
Bo Huang, Lu Tian, Enayet Talukder, Mace Rothenberg, Dae Hyun Kim, Lee-Jen Wei
No abstract text is available yet for this article.
April 19, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710136/physicians-compassion-communication-skills-and-professionalism-with-and-without-physicians-use-of-an-examination-room-computer-a-randomized-clinical-trial
#17
Ali Haider, Kimberson Tanco, Margeaux Epner, Ahsan Azhar, Janet Williams, Diane D Liu, Eduardo Bruera
No abstract text is available yet for this article.
April 19, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710090/is-there-validity-in-propensity-score-matched-estimates-of-adjuvant-chemotherapy-effects-for-patients-with-rectal-cancer
#18
George J Chang
No abstract text is available yet for this article.
April 19, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710180/estimation-of-the-percentage-of-us-patients-with-cancer-who-benefit-from-genome-driven-oncology
#19
John Marquart, Emerson Y Chen, Vinay Prasad
Importance: To date, the benefit of genome-driven cancer therapy has not been quantified. Objective: We sought to estimate the annual percentage of patients in the United States with advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug Administration (FDA)-approved genome-driven therapy from 2006 to 2018. Design, Setting, and Participants: Retrospective cross-sectional study using publically available data of (1) demographic characteristics of patients with advanced or metastatic cancer; (2) FDA data on cancer drugs approved from January 2006 through January 2018; (3) measures of response and duration of response from drug labels; and (4) published reports estimating the frequency of various genomic aberrations used to estimate what percentage of patients would have been eligible for and would have benefited from genome-driven therapy during the studied period...
April 17, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29710228/immune-profiling-of-premalignant-lesions-in-patients-with-lynch-syndrome
#20
Kyle Chang, Melissa W Taggart, Laura Reyes-Uribe, Ester Borras, Erick Riquelme, Reagan M Barnett, Guido Leoni, F Anthony San Lucas, Maria T Catanese, Federica Mori, Maria G Diodoro, Y Nancy You, Ernest T Hawk, Jason Roszik, Paul Scheet, Scott Kopetz, Alfredo Nicosia, Elisa Scarselli, Patrick M Lynch, Florencia McAllister, Eduardo Vilar
Importance: Colorectal carcinomas in patients with Lynch syndrome (LS) arise in a background of mismatch repair (MMR) deficiency, display a unique immune profile with upregulation of immune checkpoints, and response to immunotherapy. However, there is still a gap in understanding the pathogenesis of MMR-deficient colorectal premalignant lesions, which is essential for the development of novel preventive strategies for LS. Objective: To characterize the immune profile of premalignant lesions from a cohort of patients with LS...
April 16, 2018: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"